The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Urothelial Cancer Genomics

Faculty of Medicine / Department of Clinical Sciences, Lund / Section I / Urothelial cancer
Urothelial Cancer Genomics' profile in Lund University Research portal

Description

Urothelial cancer, bladder cancer, is divided in two major subtypes, non-muscle invasive and muscle-invasive, with very distinct biological and clinical properties. Prognosis and treatment are mainly based on pathological criteria. The fact that only 20-25% of high grade low stage tumors are confirmed by review pathology, and that 30% of patients with intermediate stage tumors are upstaged after repeated transurethral resection (TUR), argues that standard pathological methods is unreliable for proper tumor assessment. To address these problems we have constructed a molecular taxonomy of urothelial cancer. This taxonomy is based on a combination of gene expression, epigenetic and genomic changes, and gene mutations analyses. The overall goal is to refine and optimize UC classification into molecular subtypes important for prognosis and treatment.

Staff

B

  • Carina Bernardo

    Research project participant

    carina [dot] bernardo [at] med [dot] lu [dot] se

E

  • Pontus Eriksson

    Research project participant

    pontus [dot] eriksson [at] med [dot] lu [dot] se

H

S

  • Gottfrid Sjödahl

    Research project participant

    gottfrid [dot] sjodahl [at] med [dot] lu [dot] se